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Background: Acinetobacterbaumannii is a negative gram opportunistic bacteriumhaving high 
survival ability in the environment. Carbapenem is a drug of choice for infections caused by 
Acinetobacterbaumannii, which in the last decade prevalence of Carbapenem Resistant 
Acinetobacterbaumannii (CRAB) has increased. CRAB is commonly found in a nosocomial 
infection case and even into disease outbreak and epidemics in various hospitals. However, CRAB 
in community-associated infection data is still limited primarily in Indonesia. Therefore the 
researchers intend to do study factors causing CRAB in hospital and community setting in patients 
with Healthcare Associated Infection (HCAI). 
Subjects and Method: This study was an observational analytic study, with case control design. 
The study was conducted in RS Dr. Moewardi Surakarta in March-August 2017. Taking subject 
used fixed disease sampling method with the number of samples were 104 subjects. The dependent 
variable was the incidence of Acinetobacterbaumannii resistance to carbapenem antibiotics in 
HCAI patients. Independent variables were history of antibiotic use, patient functional status, 
intensive unit maintenance and comorbid conditions. Dependent and independent variables were 
measured by using a questionnairechecklist and then analyzed by using multiple logistic regression 
analysis. 
Results: Previous antibiotic conformity history (OR = 0.12; 95% CI = 0.03 to 0.45; p = 0.002) and 
the patient functional status (OR = 6.72; 95% CI = 2.08 to 21.68; p = 0.001) increased risk of 
resistance of Acinetobacterbaumannii to carbapenem (CRAB) in Healthcare-Associated Infections 
(HCAI) patients and was statistically significant. Treatment at intensive unit (OR = 0.76; 95% CI = 
0.26 to 2.23; p = 0.613) and comorbid conditions (OR = 0.38; 95% CI = 0.12 to 1.23; p = 0.106) 
increased risk of Acinetobacterbaumannii resistance to carbapenem (CRAB) in Healthcare 
Associated Infections (HCAI) patients although it was statistically insignificant. 
Conclusion:Previous antibiotic conformity history and functional status of patients are a factor 
affecting Acinetobacterbaumannii resistance to carbapenem (CRAB) in Healthcare-Associated 
Infections (HCAI) patients. 
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BACKGROUND 
Antibiotic Resistance (AMR) is one of the 
greatest health threats that develop from 
clinical health problems into a global public 
health problem (Schechner et al., 2013; 
WHO, 2016a). A bacterium is said to be 
resistant to antibiotics when it has changed 
its response to an antibiotic type (WHO, 
2016a), so the expected response of death 
or cessation of bacterial growth does not 
occur. The antibiotic resistance appearance 
is almost identical to the time of antibiotic 
discovery itself, for example when penicillin 
was mass-produced in 1944, three years 
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later an England doctor reported that there 
had been resistance to Staphylococcus 
pyogens bacteria against penicillin 
(Schechner et al. 2013). 
 AMR can occur if it begins with 
irrational use of antibiotics, both in the 
therapy terms (doctor) and in the consumer 
distribution (pharmacy) and when received 
by the patient (Moeloek, 2015; WHO, 
2016b). AMR cases in the United States 
resulted in death at least 23,000 people and 
in Europe at least 25,000 people per year 
(Lim et al., 2016). According to WHO data, 
Southeast Asian holds the highest number 
of AMR cases in the world. Indonesia as a 
member of the Southeast Asian country 
also takes the AMR case seriously, but 
surveillance data related to AMR mortality 
and morbidity in the field are still very 
limited (Moeloek, 2015). 
 One of the bacteria that cause AMR is 
Acinetobacterbaumannii. These bacteria 
are gram-negative bacteria that can be 
found in many places, such as on soil, 
water, human skin surfaces, equipment and 
hospital floor (Tjoaet al., 2013). A. 
baumannii is also an opportunistic bacte-
rium whose pathogenicity is low, but over 
the time, these bacteria have high patho-
genic capability because they have become 
resistant bacteria not only on one type of 
antibiotics but also on several types of 
antibiotics (Multi Drugs Resistance/ MDR) 
Adibhesamiet al., 2016; Garnacho Montero 
et al., 2016) and has been reported to have 
both Panresistance and Extremely Drug 
Resistance Acinetobacterbaumannii 
(XDRAB). 
 MDR A. Baumannii is a cause of 
increasing patient mortality and morbidity 
as well as length of hospitalization, the 
increase in patient mortality due to A. 
Baumannii is 17-46% (Tjoa et al., 2103). 
Some of the diseases often caused by A. 
Baumannii are ventilator associated 
pneumonia, urinary tract infections and 
surgical wounds, meningitis and endocar-
ditis (Lei et al., 2016). The existence of 
infection due to MDR A. baumannii makes 
the therapy choice narrower, increases 
mortality and morbidity, as well as 
increases cost and length of hospitalization, 
and makes it one of the important public 
health issues to be solved immediately 
(Chang et al. 2015; Tjoa et al., 2013). 
 Healthcare Associated Infections 
(HCAI) is an infection acquired in 
hospitalized patients over 48 hours with a 
history of previous hospital care (within 90 
days) or receiving treatment (open wound, 
intravenous injection or intravenous 
therapy) by health workers or their families 
at home (within 30 days) or routinely for 
intravenous therapy such as hemodialysis 
or chemotherapy (within 30 days) (Cardoso 
et al., 2014). Patients are exposed to HCAI 
if the first day of hospitalization does not 
get an infection, then the patient gets an 
infection after 72 hours of hospitalization 
(Taylor et al., 2016). A. baumannii is one of 
the causes of HCAI and usually these 
bacteria have become MDR bacteria. Data 
reported from the results of the 20 
provincial studies in Thailand MDR A. 
baumanni this caused the community 
acquired bacteremia by 28%, healthcare 
associated with bacteremia 50% and 75% 
hospital acquired bacterimia (p <0.001) 
(Lim et al., 2016). 
Carbapenem (meropenem, doripe-
nem, imipenem, and ertapenem) is one of 
the recommended antibiotic groups to 
address the MDR A. baumannii (Lei et al., 
2016). However, the resistance rate of A. 
baumannii to carbapenem continues to 
increase. Data from the study conducted at 
neonatal unit of RS Dr. Cipto Mangun-
kusumo Jakarta, obtained only 16% of A. 
baumanni (n = 24) isolates which were still 
sensitive to carbapenem antibiotics, where 
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the isolates from 100% blood were MDR A. 
baumannii and isolates originating from 
the environment around the patient in care 
82 % was MDR A. baumannii (Tjoaet al., 
2013). 
 Preliminary study conducted in RS 
Dr. Moewardi Surakarta on the existence of 
Carbapenem Resistant Acinetobacter-
baumannii (CRAB) had been done by 
researchers. Data from the results of the 
antibiotic resistance test of carbapenem at 
A. baumannii, during September-October 
2016, obtained 58.8% isolates were still 
sensitive to carbapenem and 41.1% of 
isolates had been resistant to carbapenem 
(n = 102). This required comprehensive 
study and follow-up because of the high 
resistance rate of A.baumanni, almost 50%, 
which made the therapeutic choice 
narrower and could increase mortality and 
morbidity. 
 Patients hospitalized for more than 48 
hours and located in intensive care unit 
(ICU) care facilities or other similar 
intensive care have been generally exposed 
to some previousantibiotics. The patient, 
treated with one or more pre-existing 
comorbid conditions, has a low functional 
status, can not undergo daily activities well 
and often needs other’s help. The patient's 
performance or functional status as 
measured by the Karnofsky Scale 
(Karnofsky Index) can provide a clinical 
picture of the patient's condition and the 
prognosis of the patient associated with the 
illness, when the patient has a karnofsky 
score <70 means that the patient is unable 
to perform normal activities, the lower the 
score,  the worse the prognosis and higher 
mortality (Cardoso et al., 2012; Peuset al., 
2013; Kelly and Shahrokni, 2016) 
 Procurement of antibiotic suscepti-
bility tests against specimens from patients 
suspected of having HCAI with comorbid 
conditions and low patient functional status 
should be a routine agenda at a hospital. 
Based on the above exposure, the 
researchers are interested in conducting 
study on the factors causing Acinetobacter-
baumannii resistance to carbapenem 
antibiotics in patients with HCAI in RS Dr. 
Moewardi Surakarta. 
 
SUBJECTS AND METHOD 
1. Study Design 
Study method was observational analytic 
study, with case control design approach. 
The time of the study was from March to 
August 2017 at Dr. Moewardi, Surakarta. 
2.Population and Sample 
The study population was patients with 
Healthcare-Associated Infections (HCAI) 
who had an infection due to Carbapenem 
Resistant Acinetobacterbaumannii (CRAB) 
in Surakarta. The study subjects were 
patients with Healthcare-Associated Infec-
tions (HCAI) who had an infection due to 
Carbapenem Resistant Acinetobacter-
baumannii (CRAB) at RS Dr. Moewardi, 
Surakarta. Subjects of 104 patients were 
selected by means of fixed disease 
sampling. 
3. Operational Definition of Variables 
Acinetobacterbaumannii resistance to 
carbapenem (CRAB) in patients with 
Healthcare-Associated Infections (HCAI) 
was defined as hospitalized patients over 48 
hours with a history of previous hospital 
care (within 90 days) or received treatment 
(within 30 days) or got routine for 
intravenous therapy such as hemodialysis 
or chemotherapy (within 30 days) 
(Friedman et al in Cardoso et al, 2014). And 
the results of sensitivity test antibiotic 
carbapenem with Vitek 2 (bioMe'rieux, 
Hazelwood, MO, USA) showed that there 
was CRAB. 
 History of previous antibiotic use was 
defined as a history of antibiotic use by 
HCAI patients when the patient received 
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empirical antibiotics for the infection as 
initial therapy. The patient's functional 
status was defined as the condition of HCAI 
patients at the time of hospitalization 
assessed from physical activity and 
patient's dependence on the surrounding. 
Treatment in an Intensive Care Unit (ICU) 
or similar intensive care was defined as a 
patient with HCAI treated at an ICU facility 
or intensive care unit (High Intensive Care 
Unit, Pediatric Intensive Care Unit, Neo- 
natal Intensive Care Unit) for more of 48 
hours. 
4. Study instrument 
Data collection instrument in this study 
was check list questionnaire, Charlson Co-
morbidity Index and Karnofsky Perfor-
mance Index. Data collection was done 
directly by researcher through direct 
interview, observation and medical record 
data. 
5. Data analysis 
Data analysis techniques used univariate, 
bivariate and multivariate analyzes. 
Univariate analysis aimed to explain each 
data characteristic. Bivariate analysis aimed 
to analyze the relationship of two variables 
using chi squaretest. Multivariate analysis 
was multiple logistic regression analysis 
which aimed to measure influence between 
more than one variable in the study. 
Researchers used SPSS version 22 to 
analyze study data. 
 
RESULTS 
A. Univariate Analysis 
Study subject characteristic included 
gender, age, treatment room and specimen 
type shown in Table 1 and Table 2. Based 
on both tables it was found that from 104 
major study subjects were male (54%). 
More than half of the study subjects were in 
the range age of 46-65 years (50.9%) and 
the rate age was 47 years. Subject majority 
treated in the care ward at Dr. Moewardi 
Hospital, were in the Orchid 1 ward 
(26.9%) and the least was from the NICU 
ward (0.9%).  
When viewed from the specimen type, 
the majority of specimens came from 
sputum (68.2%) and the least were 
bronchial aspirate and pleural specimens 
respectively of only 0.9%. Based on the 
functional status score of the patient as 
measured by PPP, the study subjects had a 
minimum value of 10 and a maximum of 60 
with an average of 38.75 and a median of 
40. 
 While patient comorbid conditions 
were measured by CCI, the study subjects 
had a minimum score of 0 and a maximum 
of 10 with an average of 2.03. 
 
Table 1. Study subject characteristic by sex and age 
Subject 
Characteristic 
Criteria Frequency (n=104) (%) 
Gender  Man  58 55.8 
 
Woman  46 43 
Age  Infant (0-5 years) 8 7.7 
 
Children (5-11 years) 3 2.9 
 
Young (12-25 years) 8 7.7 
 
Adult (26-45 years) 16 15.4 
 
Elderly (46-65 years) 53 50.9 
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Table 2. Study subject characteristic by patient care ward and specimen type 
Subject Characteristic Ward  Frequency (n=104) (%) 
Patient Care Place ICU* 10 9.6 
 
HCU Melati 1* 16 15.3 
 
Jasmine 1 9 8.6 
 
Jasmine 2 10 9.6 
 
Orchid 1 28 26.9 
 
PICU* 5 4.8 
 
NICU* 1 0.9 
 
Wing Jasmine 3 2 1.9 
 
Jasmine 2 4 3.8 
 
Jasmine 3 13 12.5 
 
Rose 1 4 3.8 
 
ROI-IGD* 2 1.9 
Gender  Sputum 71 68.2 
 
Pus 13 13.5 
 
Blood 10 8.6 
 
Urine 6 5.8 
 
Tracheal aspirate 2 1.9 
 
Bronchial aspirate 1 0.9 
 
Pleura Liquid 1 0.9 
*intensive care place 
B. Bivariate Analysis 
Table 3 showed an odds ratio of 6.76 
meaning that patients with a history of 
inadequately empirical antibiotic therapy 
had a 6.76 times greater possibility of 
triggering CRAB in patients with HCAI. 
Chi-Square test results showed that there 
was an influence of previous history of 
antibiotic use with CRAB in patients with 
HCAI and statistically significant (p = 
0.001). 
Table 3. Chi Square tests between previous antibiotic usage history, patient 
functional status, intensive care and comorbid conditions against Acinetobacter-
baumannii resistance to Carbapenem (CRAB) in patients with Healthcare-




OR 95% CI p Yes No 
n % n % n % 
Antibiotic User History          
Unsuitable 43 55.1 35 44.9 78 100 6.76 2.13 to 
21.45 
0.001 
Suitable  4 15.4 22 84.6 26 100   
Patient Functional Status         
<40 27 73 10 27 37 100 0.16 0.07 to 
0.40 
<0.001 
≥40 20 30 47 70 67 100   
Care at intensive unit          
No  21 32.8 43 67.2 64 100 3.80 
1.65 to 8.75 
0.002 
Yes 26 65 14 35 40 100   
Comorbid Condition          
<2 6 26.1 17 73.9 23 100 2.90 
1.04 to 8.11 
0.042 
≥2 41 50.6 40 49.4 81 100   
 
Indonesian Journal of Medicine (2017), 2(2): 125-138 
https://doi.org/10.26911/theijmed.2017.02.02.07 
130 e-ISSN: 2549-0265 (online) 
The odds ratio of o.16 meant that 
patients with low functional status had an 
o.16 times greater possibility of triggering 
CRAB in patients with HCAI. Chi-Square 
test results showed that there was func-
tional status influence of patients with 
CRAB in patients with HCAI and statis-
tically significant (p<0.001). 
Patients treated in intensive units had 
a 3.80 times greater possibility of triggering 
CRAB in patients with HCAI (OR= 3.80; p= 
0.002). Patients with high comorbid condi-
tions were 2.90 times greater possibility of 
triggering CRAB in patients with HCAI 
(OR= 2.90; p= 0.042). 
C. Multivariate Analysis 
Based on the above table, multiple logistic 
regression results of previous antibiotic 
conformity history (OR = 0.12; 95% CI = 
0.03 to 0.45; p= 0.002) increased risk of 
Acinetobacterbaumannii resistance to 
carbapenem (CRAB) in patients with 
Healthcare-Associated Infections (HCAI) 
statistically significant. The patient func-
tional status (OR = 6.72; 95% CI = 2.08 to 
21.68; p = 0.001) increased the risk of the 
incidence of Acinetobacterbaumannii resis-
tance to carbapenem (CRAB) in patients 
with statistically significant Healthcare-
Associated Infections (HCAI). Treatment at 
intensive units (OR = 0.76; 95% CI = 0.26 
to 2.23; p = 0.613) increased the risk of 
Acinetobacterbaumannii resistance to 
carbapenem (CRAB) in patients with 
Healthcare-Associated Infections (HCAI) 
although it was not statistically significant. 
Comorbid conditions (OR= 0.38, 95% CI= 
0.12 to 1.23, p= 0.106) increased the risk of 
Acinetobacterbaumannii resistance to 
carbapenem (CRAB) in patients with 
Healthcare-Associated Infections (HCAI) 
although it was not statistically significant. 
Table 4. Multiple Logistic Regression Test between Previous Antibiotic History, 
Patient Functional Status, Intensive Care Treatment and Comorbid Conditions 
against Acinetobacterbaumannii Resistance to Carbapenem (CRAB) in Patients 
with Healthcare-Associated Infections (HCAI) 
Variable B S.E. Wald OR 
95% CI  
p 
Lower  Upper  
Constant  -0.048 0.519 0.009 0.95  0.926  
Suitable antibiotic -2.133 0.679 9.884 0.12 0.03 0.002 0.45 
Low functional status 1.905 0.598 10.166 6.72 2.08 0.001 21.68 
Patientcared 
unintensively 
-0.279 0.552 0.255 0.76 0.26 0.613 2.23 
Low commodity score -0.975 0.604 2.611 0.38 0.12 0.106 1.23 
N observational 104       
-2log likelihood 107.33       
Nagelkerke R Square 39%       
 
DISCUSSION 
1. Effect of Previous Antibiotics 
History on Acinetobacterbaumannii 
Resistance to Carbapenem (CRAB) in 
Patients with Healthcare-Associated 
Infections (HCAI) 
There was an influence of previous history 
of antibiotic use against Acinetobacter-
baumannii resistance to carbapenem 
(CRAB) in patients with Healthcare-Asso-
ciated Infections (HCAI), got a significant 
result (p<0.001). Lin and Lan's (2014) 
study also mentioned the same that 
previous antibiotic use was an independent 
risk factor for resistance to Acinetobacter-
baumannii. 
 Kim et al., (2012) suggested that a 
previous history of high antibiotic use along 
with several other factors was an inde-
pendent risk factor for CRAB. It had also 
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been reported by Camp and Tatum (2010) 
in theirstudy, which the study mentioned 
that one of the factors that influenced the 
formation of Acinetobacterbaumannii 
resistance was due to the use of various 
antibiotics before. Use of antibiotics as an 
extensive therapy regimen is also a cause of 
Acinetobacterbaumannii resistance to 
carbapenem and other antibiotics (Bialvaei 
et al., 2017). 
 A study conducted by Peleq et al. 
(2008) showed that antibiotic treatment for 
infection therapy caused by Acinetobacter-
baumannii incorrectly triggered both 
enzymatic and non enzymatic activity of the 
bacteria to resist, so that bacteria had 
innate resistance to be resistant to certain 
antibiotics. Many other studies also suggest 
that Acinetobacterbaumannii has a 
complex intrinsic ability to withstand the 
effects of antibiotics and eventually become 
resistant (Peleq et al., 2008; Camp et al., 
2010; Giedraitiene et al., 2011; Khaldi et 
al., 2017 ; Bialvaei et al., 2017). 
 Use of antibiotics suitable for the 
treatment of bacterial infections empirically 
and definitively is absolutely necessary to 
control the existence of resistance and 
maintain antibiotic sustainability as a 
therapeutic regimen, as we know that the 
process of making and antibiotic modifica-
tion for therapy requires a considerable 
cost and a long time. Yoon et al., (2104) 
conducted a study of the carbapenem 
antibioticuse against infections caused by 
Acinetobacterbaumannii, the study cond-
ucted with an Acinetobacterbaumannii 
infection control program with the regula-
tion of the administration of the main 
empirical antibiotic (drug of choice) group 
1 carbapenem (ertapenem) and group 2 
(imipenem and meropenem) was divided 
into three phases of therapy. The study 
proved that the appropriate use of 
empirical or definitive antibiotics will be 
able to control the spread of Acinetobacter-
baumannii infection and prevent its 
resistance to carbapenem as a drug of 
choice. 
 Carbapenem-resistant acinetobacter-
baumannii is generally also resistant to two 
or more other antibiotics, especially beta-
lactam antibiotics, and the researchers also 
found a similar phenomenon in this study 
(Peleqet al., 2008; Camp et al., 2010; Lin 
and Lan, 2014; Khaldiet al., 2017; Bialvaei 
et al., 2017). Therefore Acinetobacter-
baumannii is also a multi drug resistant 
(MDR) or even excessively drug resistant 
Acinetobacterbaumannii (XDRAB) due to 
its resistance to colistin in addition to its 
resistance to other antibiotics in the list of 
Acinetobacterbaumannii (Lin and Lan, 
2014) MDR, but in this study it did not find 
any XDRAB. 
 Antimicrobial stewardship program 
is really important to do not only in 
hospital environment but also in the society 
because the development and spread of 
CRAB is high enough in various parts of the 
world which resulted in increasing 
morbidity and mortality rate as well as the 
increase of health cost which becomes 
society and state burden (Yoon et al., 2104; 
Zowawi et al., 2015). 
2. Functional Status affected Patients 
on Acinetobacterbaumannii Resis-
tance to Carbapenem (CRAB) in 
Patients with Healthcare-Associated 
Infections (HCAI) 
The study results showed a significant 
effect (p<0.001) between the patient's 
functional status against Acinetobacter-
baumannii resistance to carbapenem 
(CRAB) in patients with Healthcare-
Associated Infections (HCAI). This is based 
on Cardoso’s et al., (2012) study which 
stated that the functional status of patients 
assessed with Karnofsky Performance 
Status (KPS) is one of the risk factors for 
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infection caused by MDR bacteria in HCAI. 
One of the findings in this study was that all 
carbapenem-resistant Acinetobacterbau-
mannii were MDR bacteria. 
 The cohort study conducted by Chang 
et al. (2015) in Taiwan also supported the 
results of this study. The study was 
conducted on patients treated in long term 
care facilities (LTCFs) who suffered from 
bacterial infection, and one conclusion 
from the study that lower functional status 
(measured by PPP) was a significant 
predictive factor in all infections leading to 
death in LTCFs. The most common cases of 
LTCFs were urinary tract infection (41.7%), 
lower respiratory tract infection (32.1%) 
and infection of skin or soft tissue (27.6%), 
whereas in the study most cases were lower 
respiratory tract infection (68.2%), skin 
and soft tissue infections (13.5%) and 
bacteremia and/ or sepsis (8.6%). Other 
studies also suggested that functional dis-
ability is a risk factor for the occurrence of 
MDC Acinetobacterbaumannii colonization 
in patients (Modyet al., 2015). 
 Measuring the patient's functional 
status is important to determine the 
patient's condition regarding the prognosis 
and survival of the patient including 
knowing the severity of the disease and 
patient’snext disease end consequence (Lee 
et al., 2006; Carey et al., 2008). The lower 
the functional status of the patient, the 
worse the condition and the prognosis of 
the patient, in this study it is evident that 
the lower functional status of the patient 
has a significant effect on the occurrence of 
Acinetobacterbaumannii resistance to 
carbapenem antibiotics. Acinetobacter-
baumannii is a bacterium that has the 
ability to survive high hospital environ-
ments and has intrinsic ability to resist the 
antibiotics exposed to it, so when the 
patient has a low functional condition, it 
becomes easier for Acinetobacterbau-
mannii to cause resistance and worsen the 
patient's prognosis. 
 In this study, it was also found cases 
which the patient first examined for 
bacterial culture and antibiotic sensitivity 
test showed the results of Acinetobacter-
baumanni that was not resistant to 
carbapenem, but on the next test a few days 
later, Acinetobacterbaumannii had become 
resistant to carbapenem, the case occurred 
in patients with the PPP score in Category 
III. The average PPP score in this study was 
38.75%, and the patients in category III in 
the KPS not being able to care for 
themselves required hospital care and the 
disease could experience rapid develop-
ment (high disease progression). The 
findings of this study are consistent with 
previous studies where low PPPs contribute 
significantly to bacterial infection leading to 
higher patient mortality and a poorer 
prognosis and lower survival (Looney et al., 
2003; Lee et al. , 2006; Carey et al., 2008; 
Chang et al., 2015). 
3. Effect of Treatment on Intensive 
Units against Acinetobacterbau-
mannii Resistance to Carbapenem 
(CRAB) in Patients with Healthcare-
Associated Infections (HCAI) 
This study showed that treatment at the 
Intensive Unit increased the Acinetobacter-
baumannii resistance to carbapenem 
(CRAB) in patients with Healthcare-Asso-
ciated Infections (HCAI) although it was 
statistically insignificant. A study support-
ing the results of this study was a study 
conducted by Liu et al. (2015), one of the 
independent risk factors for the occurrence 
of bacteremia caused by MDR Acineto-
bacterbaumannii was the patient’s care 
ward in ICU. A study conducted by 
Uwingabiye, et al (2015) also explained that 
the number of patients admitted to the ICU 
infected with CRAB MDR was higher than 
that treated in the ward (non ICU) with a 
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significant difference (p<0.001). The 
results of an international study conducted 
in 2007 on infections in 1265 ICUs from 75 
different countries concluded that patients 
treated in ICU for a long time may have  
increased the risk of bacterial infections 
especially those resistant to antibiotics, one 
of which was Acinetobacter bacteria (Radji 
et al., 2011). 
 The use of invasive respiratory aids 
such as ventilators is high enough in 
intensive units, Acinetobacterbaumanniiis 
commonly found in various ventilator 
surfaces causing patients to have ventilator 
associated pneumonia (VAP), the majority 
of isolates from intensive units in this study 
were sputum, and the final diagnostic 
conclusion is VAP -Pneumonia bacterial 
etcausaAcinetobacterbaumannii.  
Study Tsakiridou et al. (2014) 
concluded that Acinetobacterbaumannii 
infection in patients treated in ICU is an 
independent risk factor for VAP events. 
Patients treated with long-term ICU 
ventilators are important risk factors for 
the occurrence of Acinetobacterbaumannii 
MDR (Arvaniti et al., 2012). 
 Most of bacterial infection outbreaks 
occurs in many ICUs and may trigger the 
occurrence of bacterial resistance epide-
mics (Vlek et al., 2013; Cheonet al., 2016). 
ICU generally contains patients with critical 
conditions requiring extended intensive 
and invasive treatment periods, putting 
patients at risk of infection. Existing 
bacteria in the ICU environment are 
opportunistic bacteria, causing no infection 
in healthy humans only colonization, but 
for these bacterial patients to be highly 
pathogenic causing therapeutic difficulty 
and longer treatment periods and high cost 
increases (Dijkshoorn et al. 2007). 
 Duijn and Bonten (2014) mentioned 
that ICU is the center of the birth of 
antibiotic-resistant Gram-negative bacte-
ria (ARGNB) resistance to antibiotic-
resistant bacteria (ARGNB) due to high 
antibiotic usage, immunological factors of 
patients in acute periods appropriate for 
bacterial infection and close contact by 
health workers with patients who facilitate 
cross-bacterial transmission. One of the 
gram-negative bacteria that is opportunistic 
then becomes highly pathogenic is Acineto-
bacterbaumannii, which triggers the 
infection outbreak in the hospital because 
the ability of colonization on the human 
body and the environment is very high 
(Dijkshoorn et al., 2007; Mamminaet al., 
2012; Duijn and Bonten, 2014; Uwingabiye 
et al., 2015; Taggart et al., 2015). 
4. Influence of Comorbid Conditions 
on Acinetobacterbaumannii Resis-
tance to Carbapenem (CRAB) in 
Patients with Healthcare-Associated 
Infections (HCAI) 
This study showed that patients with high 
comorbid conditions increased the risk of 
Acinetobacterbaumannii resistance to 
carbapenem (CRAB) in patients with 
Healthcare-Associated Infections (HCAI) 
although it was not statistically significant. 
Study conducted by Lee, et al. (2004) 
suggested that the comorbid condition of 
patients is a risk factor for the occurrence of 
carbapenem-resistant Acinetobacterbau-
mannii (imipenem). A similar study was 
also conducted by Ye et al., (2010) which 
stated that the comorbid condition of 
patients is a risk factor for the occurrence of 
MDR Acinetobacterbaumannii, specifically 
resistant to immune receptor (Imipenem 
Resistant MDR Acinetobacterbaumannii 
(IR-MDRAB). Comorbid condition was 
concluded as one of the predictors for the 
risk of bacteremia caused by Acinetobacter-
baumannii in patients treated in ICU, 
which CRAB in the same study was also a 
strong predictor factor for high mortality in 
patients (Shorr et al., 2014). 
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 According to study Chopra et al. 
(2013) comorbid conditions in patients also 
affect the occurrence of carbapenem and 
ampicillinsulbactam resistant (CASR) 
Acinetobacterbaumannii. Other studies 
have suggested that comorbid conditions 
are also independent risk factors for 
bacteremia caused by Acinetobacter-
baumannii (Chopra et al., 2014). 
Conclusions from the study of Verseleset al. 
(2013), among others, patients with high 
comorbidity based on the Charlson 
Comorbidity Index and accompanied by 
colonization of MDR bacteria may increase 
the risk of patients being admitted to 
intensive units. Other studies also suggest 
that the patient’s condition with high 
comorbidities also increases the patient 
death risk (low survival) infected by 
Acinetobacterbaumannii (Ballouz et al., 
2017). 
 Most of patients hospitalized in Dr. 
Moewardi hospital have more than one 
comorbid condition, especially if the 
patient is in the elderly age range, so at the 
time of this study, many patients had high 
comorbid conditions but were not infected 
by CRAB. This does not rule out that 
patients with high comorbid conditions will 
be infected with CRAB, because researchers 
found cases of patients who was initially 
infected byAcinetobacterbaumannii and 
still sensitive to carbapenem but on 
checking patient's culture it had been 
infected by CRAB. Patients who experience 
bacteremia caused by CRAB are generally 
in a chronic condition of a disease, high 
severity illness, high comorbidity and high 
mortality (Estherlyet al., 2011). 
 This study is the first CRAB study in 
Surakarta in HCAI patients and similar 
data in Indonesia is very limited, although 
this study also has limitations. The sample 
size in this study was 104 whereas the 
multivariate analysis chosen was multiple 
logistic regression analysis requiring large 
samples. Researchers only make suffice of 
104 samples because the study duration has 
exceeded the time period of study (5 
months to collect samples) and time 
constraints possessed by researchers during 
the study. 
 Acinetobacterbaumannii colonization 
in patients can be misinterpreted as 
patients in the control group, in this study 
the researchers can not distinguish these 
two things. To overcome this, a 
surveillance of prospective and periodic 
Acinetobacterbaumannii infection in the 
hospital areneeded. 
 Based on the results of the above 
study it can be concluded that the history of 
previous antibiotic conformity and func-
tional status of patients is a factor that 
affects the occurrence of Acinetobacter-
baumannii resistance to carbapenem 
(CRAB) in patients with Healthcare-Asso-
ciated Infections (HCAI). 
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